|
CAS Number |
Product Name |
|
187039-57-2 |
(2S,3S)-1-Boc-3-hydroxypyrrolidine-2-carboxylic acid |
|
4298-08-2 |
(2S,3R)-3-Hydroxypyrrolidine-2-carboxylic acid |
|
16626-02-1 |
6-Fluoro-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-1-carboxylic acid |
Complete series coverage, one-stop procurement. MK-0616 is a macrocyclic peptide-based PCSK9 inhibitor, and its synthesis involves the coordinated supply of multiple chiral intermediates. Cosperpharm can simultaneously provide the three core intermediates listed above, helping customers streamline supply chain management and ensure batch-to-batch consistency and compatibility.
Strict quality control, regulatory compliance. Each intermediate undergoes HPLC purity verification, chiral purity testing, and structural confirmation. Each batch is accompanied by a Certificate of Analysis (COA). For regulatory filing needs, DMF-ready documentation packages and customized quality agreements are available upon request.
Flexible supply, global delivery. From gram-scale research samples to hundred-gram process development, and to kilogram-scale production needs, Cosperpharm can provide packaging specifications and delivery cycles matching your project stage.
Enlicitide (formerly known as MK-0616) is an investigational oral PCSK9 inhibitor developed by MSD (Merck & Co., Inc., Rahway, N.J., USA). It is a novel macrocyclic peptide candidate that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors, thereby increasing the number of LDL receptors available on the cell surface to remove LDL cholesterol from the blood .
Enlicitide has the potential to be the first approved oral PCSK9 inhibitor. It is designed to deliver PCSK9 antibody-like efficacy in an easy-to-use daily pill form, addressing the critical unmet needs of patients with hypercholesterolemia . Clinical studies have shown that enlicitide decanoate significantly reduces LDL-C levels by a maximum of 66% from baseline with a good safety and tolerability profile. Its formulation with sodium caprate enabled higher bioavailability .
MSD scientists have published a landmark paper in Science magazine detailing the large-scale biocatalytic synthesis of enlicitide decanoate using a tailored suite of enzymes that catalyze selective peptide fragment formation, coupling, and macrocyclization. This strategy enabled the manufacture of a product that would not be possible with traditional synthetic methods .
To obtain quotations, samples, or technical data for the MK-0616 (Enlicitide) full series of intermediates, please contact the Cosperpharm sales and technical team. We will respond to your inquiry within 1 business day.
